Akari Therapeutics shares are up over 100% in pre-market trading after it reported breakthrough preclinical data showing its lead antibody-drug conjugate, AKTX-101, works synergistically with a KRAS inhibitor in KRAS-mutated pancreatic cancer. The result is an important scientific de-risking event for the program and supports the company's oncology pipeline. The move appears driven by investor enthusiasm around the data readout rather than broader sector news.
Akari Therapeutics shares are up over 100% in pre-market trading after it reported breakthrough preclinical data showing its lead antibody-drug conjugate, AKTX-101, works synergistically with a KRAS inhibitor in KRAS-mutated pancreatic cancer. The result is an important scientific de-risking event for the program and supports the company's oncology pipeline. The move appears driven by investor enthusiasm around the data readout rather than broader sector news.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
